Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate

被引:13
作者
Scarpazza, Cristina [2 ]
Signori, Alessio [3 ]
Cosottini, Mirco [4 ]
Sormani, Maria Pia [3 ]
Gerevini, Simonetta [5 ]
Capra, Ruggero [1 ]
机构
[1] ASST Spedali Civili Brescia, Reg Multiple Sclerosis Ctr, Via Ciotti 154, I-25018 Brescia, Italy
[2] ASST Spedali Civili Brescia, Reg Multiple Sclerosis Ctr, Montichiari, Italy
[3] Univ Genoa, Dept Hlth Sci, Genoa, Italy
[4] Univ Pisa, Dept Translat Res & New Surg & Med Technol, Pisa, Italy
[5] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Neuroradiol, Milan, Italy
关键词
Natalizumab; progressive multifocal leukoencephalopathy; lesion volume; high frequency MRI; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; MULTIPLE-SCLEROSIS; HIGHER RISK; ASYMPTOMATIC PML; RECOMMENDATIONS; DIAGNOSIS; GUIDELINES; SELECTION; SURVIVAL; PATTERN;
D O I
10.1177/1352458519854162
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Brain magnetic resonance imaging (MRI) is the most effective surveillance tool for the detection of asymptomatic progressive multifocal leukoencephalopathy (PML). However, the optimal frequency for routine MRI surveillance is under-investigated. Objective: To understand whether, upon their first MRI appearance, PML lesions present a difference in volume when comparing patients who frequently underwent MRI surveillance (3/4 months) with those who were assessed at longer intervals (6/12 months) and to understand the impact of the volume of lesions on clinical outcome. Methods: The data of patients included in the Italian PML cohort were retrospectively analysed. Patients who had all the pre-diagnostic MRI scans available (n = 37) were included. The volume of PML lesion was calculated by manually outlining the PML lesion. Results: Compared with patients who underwent MRI examination at least every 4 months, patients who were assessed less frequently had a lesion of significantly higher volume (median: 2567 (883-3583) vs. 664 mm(3)(392-963)p = 0.006) and suffered a higher rate of disability (median: 2.25 expanded disability status scale points (-2.5 to 8) vs. 0.5 (-1 to 2.5)p = 0.004). Conclusion: The positive clinical outcome of patients undergoing frequent MRI surveillance and the small volume of the PML lesion upon first appearance justify a frequent surveillance using MRI in patients at high risk of PML.
引用
收藏
页码:1227 / 1236
页数:10
相关论文
共 40 条
[1]   Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples [J].
Austin, Peter C. .
STATISTICS IN MEDICINE, 2009, 28 (25) :3083-3107
[2]   Value of MRI as a surrogate marker for PML in natalizumab long-term therapy [J].
Ayzenberg, I. ;
Lukas, C. ;
Trampe, N. ;
Gold, R. ;
Hellwig, K. .
JOURNAL OF NEUROLOGY, 2012, 259 (08) :1732-1733
[3]   Classifying PML risk with disease modifying therapies [J].
Berger, Joseph R. .
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 12 :59-63
[4]   PML diagnostic criteria Consensus statement from the AAN Neuroinfectious Disease Section [J].
Berger, Joseph R. ;
Aksamit, Allen J. ;
Clifford, David B. ;
Davis, Larry ;
Koralnik, Igor J. ;
Sejvar, James J. ;
Bartt, Russell ;
Major, Eugene O. ;
Nath, Avindra .
NEUROLOGY, 2013, 80 (15) :1430-1438
[5]   NATALIZUMAB-ASSOCIATED PML IDENTIFIED IN THE PRESYMPTOMATIC PHASE USING MRI SURVEILLANCE [J].
Blair, Nicholas F. ;
Brew, Bruce J. ;
Halpern, Jean-Pierre .
NEUROLOGY, 2012, 78 (07) :507-508
[6]   Subjective recollection independent from multifeatural context retrieval following damage to the posterior parietal cortex [J].
Ciaramelli, Elisa ;
Faggi, Giorgia ;
Scarpazza, Cristina ;
Mattioli, Flavia ;
Spaniol, Julia ;
Ghetti, Simona ;
Moscovitch, Morris .
CORTEX, 2017, 91 :114-125
[7]   Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy [J].
Coyle, Patricia K. ;
Foley, John F. ;
Fox, Edward J. ;
Jeffery, Douglas R. ;
Munschauer, Frederick E., III ;
Tornatore, Carlo .
MULTIPLE SCLEROSIS JOURNAL, 2009, 15 :S26-S36
[8]   Outcome and survival of asymptomatic PML in natalizumab-treated MS patients [J].
Dong-Si, Tuan ;
Richman, Sandra ;
Wattjes, Mike P. ;
Wenten, Made ;
Gheuens, Sarah ;
Philip, Jeffrey ;
Datta, Shoibal ;
McIninch, James ;
Bozic, Carmen ;
Bloomgren, Gary ;
Richert, Nancy .
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2014, 1 (10) :755-764
[9]   High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO [J].
Enzinger, Christian .
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (06) :767-770
[10]   Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging [J].
Hodel, Jerome ;
Outteryck, Olivier ;
Dubron, Celine ;
Dutouquet, Bastien ;
Benadjaoud, Mohamed Amine ;
Duhin, Emeline ;
Verclytte, Sebastien ;
Zins, Marc ;
Luciani, Alain ;
Rahmouni, Alain ;
Pruvo, Jean-Pierre ;
Vermersch, Patrick ;
Leclerc, Xavier .
RADIOLOGY, 2016, 278 (03) :863-872